The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial.

ABSTRACT:

Background

The V2 receptor antagonist tolvaptan is prescribed to patients with autosomal dominant polycystic kidney disease to slow disease progression. Tolvaptan may alter BP via various acute and chronic effects.

Methods

To investigate the magnitude and time course of the effect of tolvaptan use on BP, we conducted a post hoc study of the TEMPO 3:4 trial, which included 1445 patients with autosomal dominant polycystic kidney disease randomized 2:1 to tolvaptan or placebo for 3 years. We evaluated systolic and diastolic BP, mean arterial pressure, hypertension status, and use and dosing of antihypertensive drugs over the course of the trial.

Results

At baseline, BP did not differ between study arms. After 3 weeks of tolvaptan use, mean body weight had d

SUBMITTER: Heida JE 

PROVIDER: S-EPMC8425647 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature